Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Identifieur interne : 001659 ( PubMed/Corpus ); précédent : 001658; suivant : 001660Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Auteurs : A. Boireau ; J M Miquet ; P. Dubédat ; M. Meunier ; A. DobleSource :
- Neuroreport [ 0959-4965 ] ; 1994.
English descriptors
- KwdEn :
- 1-Methyl-4-phenylpyridinium (antagonists & inhibitors), 3,4-Dihydroxyphenylacetic Acid (metabolism), Animals, Corpus Striatum (drug effects), Corpus Striatum (metabolism), Dopamine (metabolism), Excitatory Amino Acid Antagonists, Extracellular Space (metabolism), Homovanillic Acid (metabolism), Male, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Rats, Riluzole, Thiazoles (pharmacology).
- MESH :
- chemical , antagonists & inhibitors : 1-Methyl-4-phenylpyridinium.
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Dopamine, Homovanillic Acid.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Corpus Striatum.
- drug therapy : Parkinson Disease, Secondary.
- metabolism : Corpus Striatum, Extracellular Space.
- chemical , pharmacology : Thiazoles.
- Animals, Excitatory Amino Acid Antagonists, Male, Rats, Riluzole.
Abstract
Superfusion of the rat striatum with 100 microM of 1-methyl-4-phenylpyridinium (MPP+) induced a 70-fold increase in dopamine (DA) release and a decrease in the extracellular levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Pretreatment with riluzole (8 mg kg-1, i.p.), a compound that interferes with glutamatergic transmission, partially antagonized the effect of MPP+ on the release of DA, but did not change the effects of this toxin on the efflux of DOPAC and HVA. Riluzole did not affect the increase in DA release induced by MPP+ in vitro. The in vivo efficacy of riluzole on MPP(+)-induced DA release could be due to its central interference with glutamatergic transmission. Our data point to a protective role of riluzole with regard to DA release, a marker of the neuronal impairment induced by MPP+, a pro-parkinsonian neurotoxin.
PubMed: 7865766
Links to Exploration step
pubmed:7865766Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.</title><author><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name><affiliation><nlm:affiliation>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Département Biologie, Vitry-sur-Seine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Miquet, J M" sort="Miquet, J M" uniqKey="Miquet J" first="J M" last="Miquet">J M Miquet</name></author><author><name sortKey="Dubedat, P" sort="Dubedat, P" uniqKey="Dubedat P" first="P" last="Dubédat">P. Dubédat</name></author><author><name sortKey="Meunier, M" sort="Meunier, M" uniqKey="Meunier M" first="M" last="Meunier">M. Meunier</name></author><author><name sortKey="Doble, A" sort="Doble, A" uniqKey="Doble A" first="A" last="Doble">A. Doble</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7865766</idno><idno type="pmid">7865766</idno><idno type="wicri:Area/PubMed/Corpus">001659</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001659</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.</title><author><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name><affiliation><nlm:affiliation>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Département Biologie, Vitry-sur-Seine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Miquet, J M" sort="Miquet, J M" uniqKey="Miquet J" first="J M" last="Miquet">J M Miquet</name></author><author><name sortKey="Dubedat, P" sort="Dubedat, P" uniqKey="Dubedat P" first="P" last="Dubédat">P. Dubédat</name></author><author><name sortKey="Meunier, M" sort="Meunier, M" uniqKey="Meunier M" first="M" last="Meunier">M. Meunier</name></author><author><name sortKey="Doble, A" sort="Doble, A" uniqKey="Doble A" first="A" last="Doble">A. Doble</name></author></analytic><series><title level="j">Neuroreport</title><idno type="ISSN">0959-4965</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenylpyridinium (antagonists & inhibitors)</term><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term><term>Animals</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Dopamine (metabolism)</term><term>Excitatory Amino Acid Antagonists</term><term>Extracellular Space (metabolism)</term><term>Homovanillic Acid (metabolism)</term><term>Male</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Rats</term><term>Riluzole</term><term>Thiazoles (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>1-Methyl-4-phenylpyridinium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term><term>Dopamine</term><term>Homovanillic Acid</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Extracellular Space</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Thiazoles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Excitatory Amino Acid Antagonists</term><term>Male</term><term>Rats</term><term>Riluzole</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Superfusion of the rat striatum with 100 microM of 1-methyl-4-phenylpyridinium (MPP+) induced a 70-fold increase in dopamine (DA) release and a decrease in the extracellular levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Pretreatment with riluzole (8 mg kg-1, i.p.), a compound that interferes with glutamatergic transmission, partially antagonized the effect of MPP+ on the release of DA, but did not change the effects of this toxin on the efflux of DOPAC and HVA. Riluzole did not affect the increase in DA release induced by MPP+ in vitro. The in vivo efficacy of riluzole on MPP(+)-induced DA release could be due to its central interference with glutamatergic transmission. Our data point to a protective role of riluzole with regard to DA release, a marker of the neuronal impairment induced by MPP+, a pro-parkinsonian neurotoxin.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7865766</PMID><DateCreated><Year>1995</Year><Month>03</Month><Day>30</Day></DateCreated><DateCompleted><Year>1995</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0959-4965</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>16</Issue><PubDate><Year>1994</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Neuroreport</Title><ISOAbbreviation>Neuroreport</ISOAbbreviation></Journal><ArticleTitle>Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.</ArticleTitle><Pagination><MedlinePgn>2157-60</MedlinePgn></Pagination><Abstract><AbstractText>Superfusion of the rat striatum with 100 microM of 1-methyl-4-phenylpyridinium (MPP+) induced a 70-fold increase in dopamine (DA) release and a decrease in the extracellular levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Pretreatment with riluzole (8 mg kg-1, i.p.), a compound that interferes with glutamatergic transmission, partially antagonized the effect of MPP+ on the release of DA, but did not change the effects of this toxin on the efflux of DOPAC and HVA. Riluzole did not affect the increase in DA release induced by MPP+ in vitro. The in vivo efficacy of riluzole on MPP(+)-induced DA release could be due to its central interference with glutamatergic transmission. Our data point to a protective role of riluzole with regard to DA release, a marker of the neuronal impairment induced by MPP+, a pro-parkinsonian neurotoxin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boireau</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Département Biologie, Vitry-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miquet</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Dubédat</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Meunier</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Doble</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuroreport</MedlineTA><NlmUniqueID>9100935</NlmUniqueID><ISSNLinking>0959-4965</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>102-32-9</RegistryNumber><NameOfSubstance UI="D015102">3,4-Dihydroxyphenylacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>R865A5OY8J</RegistryNumber><NameOfSubstance UI="D015655">1-Methyl-4-phenylpyridinium</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X77S6GMS36</RegistryNumber><NameOfSubstance UI="D006719">Homovanillic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015655" MajorTopicYN="N">1-Methyl-4-phenylpyridinium</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015102" MajorTopicYN="N">3,4-Dihydroxyphenylacetic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="Y">Excitatory Amino Acid Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006719" MajorTopicYN="N">Homovanillic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>10</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>10</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7865766</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001659 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001659 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7865766
|texte= Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7865766" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |